
Ardent Health Prices $116 Million Secondary Stock Offering and Plans Concurrent Repurchase of 1.5 Million Shares
Company Announces Pricing of 8 Million Shares Offered by Existing Stockholders
Ardent Health, referred to as “Ardent Health” or the “Company,” has announced the pricing of its previously disclosed secondary public offering of 8 million shares of common stock. The offering will involve shares being sold by existing stockholders affiliated with Equity Group Investments and Ventas, Inc. The shares have been priced at $14.50 each, establishing a total public offering value of approximately $116 million before any underwriting discounts, commissions or other applicable expenses. The announcement marks another development in Ardent Health’s capital markets activity and provides details about the planned sale of shares by the two existing investors.
The secondary offering consists of 7,136,719 shares held by an affiliate of Equity Group Investments and 863,281 shares held by an affiliate of Ventas, Inc. Together, these entities are identified as the “Selling Stockholders” in the company’s announcement. The transaction will allow the Selling Stockholders to offer part of their existing ownership in Ardent Health to public investors. Importantly, the shares are not being issued as new shares by Ardent Health. Instead, the offering involves existing common stock held by the Selling Stockholders, meaning the company itself is not raising capital through the sale.
The public offering price has been set at $14.50 per share. Based on the announced offering size of 8 million shares, the transaction represents approximately $116 million in gross value at the public offering price. The final amount received by the Selling Stockholders will be subject to underwriting discounts, commissions and other applicable transaction costs. The offering is expected to close on November 19, 2026, subject to the satisfaction of customary closing conditions. Completion of the transaction will depend on the applicable closing requirements being met.
Underwriters Receive a 30-Day Option for Additional Shares
As part of the offering arrangements, the Selling Stockholders have granted the underwriters a 30-day option to purchase up to an additional 1.2 million shares of Ardent Health common stock. This option is intended to provide the underwriters with flexibility to purchase additional shares at the same public offering price of $14.50 per share, less the underwriting discounts and commissions. The additional shares, if purchased through the exercise of the option, will also come from the holdings of the Selling Stockholders rather than from a new issuance by Ardent Health.
The option could increase the total number of shares sold in the transaction beyond the initially announced 8 million shares. If the underwriters exercise the option in full, an additional 1.2 million shares would be included in the offering. At the public offering price, those additional shares would represent a gross value of $17.4 million before underwriting discounts and commissions. However, the option is not an automatic part of the initial offering size, and the actual number of additional shares sold will depend on whether the underwriters choose to exercise it within the specified 30-day period.
The Selling Stockholders are responsible for offering all shares included in the transaction, including any shares that may be sold through the exercise of the underwriters’ additional share option. Ardent Health has clarified that it is not selling any common stock as part of the offering. This distinction is important because the transaction is a secondary offering, in which existing shareholders sell shares they already own, rather than a primary offering in which a company issues new shares to raise funds for its business.
Ardent Health to Repurchase 1.5 Million Shares Concurrently
Alongside the secondary offering, Ardent Health plans to carry out a concurrent share repurchase, subject to the completion of the offering. Under this arrangement, the company intends to repurchase 1.5 million shares of its common stock from the underwriters. These shares will be part of the shares being sold through the secondary offering. The repurchase price per share will be equal to the price per share paid by the underwriters to the Selling Stockholders.
The planned repurchase represents a separate but related component of the overall transaction. While the Selling Stockholders are offering 8 million shares to public investors, Ardent Health intends to buy back 1.5 million shares from the underwriters at the applicable purchase price. At the stated public offering price of $14.50 per share, the 1.5 million shares represent a value of approximately $21.75 million. The actual repurchase payment will be based on the price paid by the underwriters to the Selling Stockholders, as specified in the company’s announcement.
Ardent Health intends to finance the concurrent share repurchase using its existing cash on hand. The company has not indicated that it plans to use proceeds from the secondary offering to fund the repurchase. This is because the proceeds from the sale of shares by the Selling Stockholders will go to those selling shareholders, rather than to Ardent Health. The company will therefore use its own available cash to complete the planned purchase of the 1.5 million shares.
The company also clarified that this concurrent share repurchase is not being conducted under its previously disclosed stock repurchase plan. As a result, the transaction will not reduce the amount of repurchase capacity available under that existing plan. This means the company intends to treat the concurrent repurchase as a separate transaction rather than using the authorization available under its previously announced share repurchase program.
Underwriters Will Not Receive Compensation for Repurchased Shares
Ardent Health has also provided clarification about the compensation arrangements connected to the concurrent share repurchase. The underwriters will not receive any compensation for the shares that are being repurchased by the company. This provision distinguishes the repurchased portion from the shares that are being distributed to public investors through the secondary offering.
The announcement further states that the secondary offering is not conditioned upon the completion of the concurrent share repurchase. In practical terms, the offering can proceed independently of the company’s planned repurchase. Although both transactions are being announced together and are expected to take place in connection with one another, the completion of the offering does not depend on the company completing the repurchase. This provides an important distinction between the two arrangements and clarifies that they are not structured as a single transaction with mutually dependent closing requirements.
The concurrent share repurchase will be subject to the completion of the offering, according to the company’s announcement. The company has not provided additional details about any changes to the repurchase plan or future buyback activity beyond the information disclosed in this transaction. Its announcement specifically confirms that the 1.5 million-share purchase will not reduce the capacity available under the previously disclosed stock repurchase plan.
Investment Banks Appointed to Manage the Offering
Several financial institutions have been appointed to manage the secondary offering. J.P. Morgan and Barclays are serving as the lead book-running managers. Their responsibilities include leading the book-building process and coordinating the offering with participating investors and other underwriting institutions.
BofA Securities, Citigroup, Leerink Partners, Mizuho, RBC Capital Markets, Stephens Inc. and Truist Securities are also acting as bookrunners. These institutions are participating in the management and distribution of the offering alongside the lead book-running managers. Capital One Securities has been appointed as co-manager for the transaction.
The involvement of these financial institutions establishes the underwriting and management group responsible for supporting the public offering. The announcement identifies the roles of the participating banks but does not provide additional details about the allocation of shares among investors or the level of demand received during the offering process. The transaction is expected to close on November 19, 2026, subject to customary closing conditions.
Prospectus Documents Available Through SEC and Underwriters
Ardent Health stated that the proposed secondary offering will be made only through a prospectus supplement and the accompanying prospectus. These documents contain the formal information relating to the securities being offered and the terms of the transaction. Once available, copies of the final prospectus supplement and accompanying prospectus may be obtained through the designated contacts at J.P. Morgan Securities LLC and Barclays Capital Inc.
Investors seeking documents through J.P. Morgan Securities LLC may contact the firm through Broadridge Financial Solutions at 1155 Long Island Avenue, Edgewood, New York 11717. The announcement also provides the email addresses [email protected] and [email protected] for document requests. For Barclays Capital Inc., investors may contact Broadridge Financial Solutions at the same Edgewood, New York address, call 1-888-603-5847 or email [email protected].
The company has also directed investors to the website of the U.S. Securities and Exchange Commission, where the relevant offering documents can be accessed through the SEC’s EDGAR database. The documents may be obtained free of charge by visiting www.sec.gov. Access to the prospectus materials allows investors to review the formal details of the offering, including the securities involved and the applicable transaction information.
Registration Statement and Regulatory Information
Ardent Health confirmed that a registration statement on Form S-3 relating to the offering was declared effective by the SEC on August 25, 2025. A preliminary prospectus supplement relating to the secondary offering has also been filed with the SEC, and the company stated that a final prospectus supplement will be filed as well. These filings form part of the regulatory documentation associated with the public offering.
The company emphasized that the press release itself does not constitute an offer to sell securities or a solicitation of an offer to buy securities. It also clarified that the securities will not be sold in any state or jurisdiction where such an offer, solicitation or sale would be unlawful before registration or qualification under the applicable securities laws. Any offers, solicitations or sales connected with the transaction will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
This regulatory statement highlights that investors should rely on the formal prospectus documentation for information about the offering. The press release provides an announcement of the pricing and transaction structure, while the prospectus supplement and accompanying prospectus contain the formal offering materials. The company has directed interested parties to the SEC and the underwriters for access to those documents.
Transaction Combines Shareholder Sale With Company Repurchase
The announced transaction combines a secondary share sale by existing stockholders with a separate concurrent repurchase by Ardent Health. The Selling Stockholders are offering 8 million shares at $14.50 per share, with a 30-day option available to underwriters to purchase up to another 1.2 million shares. Ardent Health, meanwhile, plans to repurchase 1.5 million shares from the underwriters using its existing cash on hand, subject to completion of the offering.
The company will not receive proceeds from the secondary offering because the shares are being sold by the existing stockholders. The concurrent repurchase will be financed separately and will not be conducted under the previously disclosed stock repurchase plan. Ardent Health has also confirmed that the repurchase will not reduce the available capacity under that plan, while the underwriters will receive no compensation for the shares being repurchased.
With the offering priced at $14.50 per share and closing expected on November 19, 2026, the transaction represents a planned change in the ownership of Ardent Health’s common stock, alongside a company-funded share repurchase. The final completion of the offering remains subject to customary closing conditions, and the additional share option will remain available to the underwriters for 30 days. Through its announcement, Ardent Health has outlined the share sale, repurchase arrangements, financial responsibilities and regulatory documentation associated with the transaction.
Source link: https://ardenthealth.com/





